Shanghai Serum Bio-Technology Co., Ltd. (SHA:688163)

SHA:688163 Revenue

Shanghai Serum Bio-Technology had revenue of 68.80M CNY in the quarter ending September 30, 2026, a decrease of -7.42%. This brings the company's total for the last twelve months to 194.08M, down -1.36% year-over-year. In the year 2025, Shanghai Serum Bio-Technology had annual revenue of 196.21M with 0.66% growth. That makes Shanghai Serum Bio-Technology the 31,559th largest company in the world by revenue and 5,020th in China.

• Revenue (ttm): 194.08M
• Revenue Growth: -1.36%
• P/S Ratio: 17.50
• Revenue / Employee: 577.62K
• Employees: 336
• Market Cap: 3.40B

Revenue Chart

Chart

Chart

Revenue by Geography

Chart

• China 194.49M 99.1%
• Overseas 1.72M 0.9%

Fiscal year ended Dec 31, 2025 See the full SHA:688163 breakdown

Revenue History

Fiscal Year End	Revenue	Change	Growth
Dec 31, 2025	196.21M	1.29M	0.66%
Dec 31, 2024	194.92M	4.77M	2.51%
Dec 31, 2023	190.14M	15.92M	9.14%
Dec 31, 2022	174.22M	-34.47M	-16.52%
Dec 31, 2021	208.69M	23.13M	12.47%

Data Source: S&P Global Market Intelligence Last updated: Oct 27, 2026

Revenue data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Nov 3, 2026

Data Sources Report a data error